Lacipil

Lacidipine, the active ingredient in Lacipil, is a calcium channel blocker presented as an oral tablet for oral use. It treats hypertension in adults. GNH USA supplies Lacipil as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacidipine is used to manage high blood pressure by acting on the vascular smooth muscle system.

Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of cardiovascular events.

Lacidipine may cause several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: transient warmth and redness of the skin. - Peripheral edema: swelling of the ankles or feet. - Dizziness: sensation of light‑headedness, especially on standing.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of the face, lips, tongue, or throat. - Hepatic dysfunction: abnormal liver enzyme elevations. - Cardiac arrhythmia: irregular heart rhythm that may be life‑threatening.

Before prescribing Lacipil, clinicians should consider several safety aspects.

Monitor blood pressure regularly: ensure therapeutic effect and avoid excessive hypotension. Avoid abrupt discontinuation: taper dose to prevent rebound hypertension. Use caution in hepatic impairment: dose adjustment may be required. Use caution in elderly patients: increased sensitivity to blood‑pressure lowering effects. Avoid concomitant use with strong CYP3A4 inhibitors: may increase Lacidipine plasma levels. Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Lacidipine can interact with other medicines, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise Lacidipine concentrations. - Grapefruit juice: can increase drug exposure and risk of hypotension. - Other antihypertensives causing additive blood‑pressure reduction.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce Lacidipine effectiveness. - Diuretics: may enhance orthostatic hypotension. - Beta‑blockers: may require dose adjustments to avoid excessive heart‑rate slowing.